Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Blueprint Medi Cm ST (BPMC)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
[[ ctrl.chartTitle ]]
Full Chart

Fundamentals

See More
  • Market Capitalization, $K 2,175,755
  • Shares Outstanding, K 39,020
  • Annual Sales, $ 27,770 K
  • Annual Income, $ -72,500 K
  • 36-Month Beta 1.25
  • Price/Sales 77.65
  • Price/Cash Flow 0.00
  • Price/Book 11.20

Price Performance

See More
Period Period Low Period High Performance
1-Month
48.87 +12.54%
on 06/28/17
56.81 -3.19%
on 07/21/17
+5.76 (+11.70%)
since 06/27/17
3-Month
34.38 +59.98%
on 05/31/17
56.81 -3.19%
on 07/21/17
+9.00 (+19.57%)
since 04/27/17
52-Week
20.62 +166.73%
on 08/02/16
56.81 -3.19%
on 07/21/17
+33.25 (+152.87%)
since 07/27/16

Most Recent Stories

More News
Blueprint Medicines to Evaluate Opportunities to Advance Rare Disease Discovery Program in Fibrodysplasia Ossificans Progressiva Following Discontinuation of Collaboration with Alexion

Blueprint Medicines Corporation (NASDAQ: BPMC), a leader in discovering and developing targeted kinase medicines for patients with genomically defined diseases, today announced plans to evaluate opportunities...

BPMC : 55.28 (-0.86%)
Blueprint Medicines to Report Second Quarter 2017 Financial Results on Wednesday, August 2, 2017

Blueprint Medicines Corporation (NASDAQ: BPMC), a leader in discovering and developing targeted kinase medicines for patients with genomically defined diseases, today announced that it will host a live...

BPMC : 55.28 (-0.86%)
Uptrend Call Working As Blueprint Medici Stock Rises 40.7% (BPMC)

SmarTrend identified an Uptrend for Blueprint Medici (NASDAQ:BPMC) on June 16th, 2017 at $39.29. In approximately 1 month, Blueprint Medici has returned 40.67% as of today's recent price of $55.27.

BPMC : 55.28 (-0.86%)
Blueprint Medici Shares Up 36.0% Since SmarTrend's Buy Recommendation (BPMC)

SmarTrend identified an Uptrend for Blueprint Medici (NASDAQ:BPMC) on June 16th, 2017 at $39.29. In approximately 1 month, Blueprint Medici has returned 35.99% as of today's recent price of $53.43.

BPMC : 55.28 (-0.86%)
Blueprint Medicines (BPMC) Shows Strength: Stock Adds 9.6% in Session

Blueprint Medicines Corporation (BPMC) was a big mover last session, as the company saw its shares rise nearly 10% on the day.

ENZ : 11.31 (+0.18%)
BPMC : 55.28 (-0.86%)
Blueprint Medicines Announces New Phase 1 Clinical Data for BLU-285 in Advanced Gastrointestinal Stromal Tumors and Plans to Pursue Expedited Development in Patients with a PDGFRa D842V Mutation

Blueprint Medicines Corporation (NASDAQ: BPMC), a leader in discovering and developing targeted kinase medicines for patients with genomically defined diseases, today announced new Phase 1 clinical data...

BPMC : 55.28 (-0.86%)
Blueprint Medicines to Present at Upcoming Investor Conferences in June

Blueprint Medicines Corporation (NASDAQ: BPMC), a leader in discovering and development targeted kinase medicines for patients with genomically defined diseases, today announced its participation in the...

BPMC : 55.28 (-0.86%)
Investor Network: Blueprint Medicines Corp. to Host Earnings Call

NEW YORK, NY / ACCESSWIRE / May 3, 2017 / Blueprint Medicines Corp. (NASDAQ: BPMC) will be discussing their earnings results in their Q1 Earnings Call to be held May 3, 2017 at 8:30 AM Eastern Time.

BPMC : 55.28 (-0.86%)
Blueprint Medicines Reports First Quarter 2017 Financial Results

Blueprint Medicines Corporation (NASDAQ: BPMC), a leader in discovering and developing targeted kinase medicines for patients with genomically defined diseases, today reported financial results and provided...

BPMC : 55.28 (-0.86%)
Blueprint Medicines to Report First Quarter 2017 Financial Results on Wednesday, May 3, 2017

Blueprint Medicines Corporation (NASDAQ: BPMC), a leader in discovering and developing targeted kinase medicines for patients with genomically defined diseases, today announced that it will host a live...

BPMC : 55.28 (-0.86%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 80% Buy with a Weakest short term outlook on maintaining the current direction.

Longer term, the trend strength is Strong. Long term indicators fully support a continuation of the trend.

See More

Business Summary

Blueprint Medicines Corp is an oncology company which is engaged in developing kinase inhibitors for genomically defined cancer subsets. Blueprint Medicines Corp is based in Cambridge, MA.

See More

Support & Resistance

2nd Resistance Point 56.90
1st Resistance Point 56.33
Last Price 55.28
1st Support Level 55.08
2nd Support Level 54.40

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.